Two Sigma Ventures Spins Out as Deviation Capital With $2B AUM and a Reset on Quant-Native VC
TL;DR
Two Sigma Ventures, the 14-year-old early-stage venture arm of quant trading giant Two Sigma, has spun out and rebranded as Deviation Capital. The independent firm launches with about $2 billion in assets under management, 79 active portfolio companies including WHOOP, Remote, Xaira, Kalshi, Gameto and Etched, and continued access to Two Sigma's senior technical talent. Founding partners include Colin Beirne (who built the original platform), Dusan Perovic, Sidney Costabile, and former NEA partner Jonathan Golden, who runs the new San Francisco office. The thesis is unchanged: back technical founders building data and compute-native companies at Seed and Series A.
Key Takeaways
This is a clean spinout, not a workout. Deviation has acquired management of certain existing TSV funds, the team is intact, the LPs went with the GP, and the brand is new. That distinguishes this from the typical "founders left to start a new firm" spinout. The continuity matters because $2B in AUM is non-trivial and means the fee stream is real on day one.
Quant-native VC is having a moment. The pitch that AI and machine learning expertise gives a venture firm an edge in diligence and portfolio support has been around for over a decade. Two Sigma was one of the original instances of that thesis. Now that AI-native investing is finally in vogue, Deviation gets to relaunch the brand at exactly the moment the market wants this story. Lucky timing, or smart timing.
The portfolio is what makes the relaunch credible. WHOOP is a unicorn consumer hardware brand. Kalshi is the Trump-trade poster child of regulated prediction markets. Etched is one of the most-talked-about AI inference chip startups. Xaira is the AI-for-drug-discovery juggernaut backed by ARCH and Foresite. Remote built a global employer-of-record category. That is a portfolio with multiple plausible $1B+ markup paths and a real shot at distributions in the next 24 months.
Independence is the right call for this market. Corporate venture inside a hedge fund or quant trading firm has always carried baggage: regulatory entanglement, comp friction, fundraising opacity. As AI-native venture matures, sophisticated LPs want clean independent GPs they can underwrite as managers, not as cost centers of a parent. Deviation's structure now matches its market.
Fund Overview
Fund Name: Deviation Capital (multiple existing funds under management)
Fund Size: Approximately $2 billion in assets under management at launch
Stage: Seed and Series A early-stage
Check Size: Not disclosed; consistent with sub-$10M early-stage cheques based on portfolio composition
Geography: United States primarily, offices in New York and San Francisco
Focus: Technical founders applying data and compute to consumer, enterprise, and life sciences problems
Key LPs: Not disclosed; existing TSV LPs migrated with the spinout
Why This Fund Matters
Two Sigma Ventures was one of the more interesting hybrid platforms in the venture industry. It had access to one of the most respected quantitative research and engineering organizations in finance, and it was meaningfully early on the AI/ML investing thesis well before the GenAI cycle made it fashionable. The portfolio reflects that. WHOOP, Etched, Kalshi and Xaira are not opportunistic AI plays. They are deeply technical companies that benefit from a firm that can credibly evaluate compute, data, and inference architectures.
The independence move is a recognition that the venture market has changed since TSV was incubated. In 2012, attaching an early-stage fund to a brand-name quant shop signaled rigor. In 2026, with AI-native investing now mainstream, sophisticated founders and LPs increasingly prefer independent managers with clear GP economics, dedicated boards and uncomplicated brand identity. By spinning out cleanly while retaining a relationship with Two Sigma's technical bench, Deviation gets the best of both worlds: GP autonomy plus a unique sourcing and diligence advantage that few competitors can match.
It is also a useful reminder that big-tent fund families and corporate venture programs are not the natural end state for top-quartile early-stage investing. Long-tenured operators like Colin Beirne tend to want optionality on succession, fund mechanics, and LP composition that corporate parents cannot always offer. Expect more spinouts of this type over the next 24 months as institutional venture programs at banks, insurers, and trading firms get pressure-tested by their parent companies' return targets.
The competitive set Deviation now sits in is crowded but distinct. Founders Fund, Lux, USV, Khosla, and Spark all play in technical early-stage. What Deviation has that few others can claim is a deeply embedded relationship with a quant trading firm whose internal infrastructure is among the most sophisticated in private finance. If they can productize that into diligence support, technical co-development, and recruiting, the moat is real.
The Team
Colin Beirne is the firm's anchor. He founded the predecessor TSV platform more than a decade ago and remains the operator most responsible for the portfolio's technical quality. Dusan Perovic leads investments in data science and life sciences, including positions in companies like Xaira. Sidney Costabile heads capital markets and is the partner most responsible for the fundraising and LP-side operations. Jonathan Golden, a former NEA general partner who also ran product at Airbnb, joins as a founding partner and runs the San Francisco office. That is a senior, balanced bench, with one ex-mega-fund GP added specifically to deepen West Coast presence and product judgment.
The continuing relationship with Two Sigma is the team's secret weapon. Deviation maintains formal access to senior technical experts at the parent firm spanning data science, AI, engineering and applied research. For founders building in inference infrastructure, biotech AI, or quantitative life sciences, that kind of consult-on-demand access is rare and difficult to replicate.
Early Portfolio
Deviation launches with 79 active portfolio companies inherited from the TSV platform. Notable names include WHOOP (consumer health wearables), Remote (global employment infrastructure), Xaira Therapeutics (AI for drug discovery), Kalshi (regulated prediction markets), Gameto (women's health and reproductive biology) and Etched (specialized AI inference silicon). The portfolio also spans dozens of less-publicized seed and Series A bets that will define Deviation's underlying performance over the next decade.
What This Means for Founders
If you are a technical founder building an AI-native company at Seed or Series A, Deviation should be a default meeting, especially in the New York and San Francisco markets. The diligence will be unusually deep. The reference checks on your technology will be more rigorous than at most generalist shops. And the post-investment support, including access to senior Two Sigma technical talent, is genuinely differentiated.
Two cautions. First, the bar is high. Deviation's portfolio is heavily weighted toward founders with non-trivial technical depth. Bring the engineering. Second, expect a longer diligence cycle than at the speed-first early-stage shops. The firm's value-add is rooted in technical rigor, and that takes time. Plan accordingly when running your process.
Fund Momentum Take
The spinout is the right move at the right time. Two Sigma Ventures was one of the more underappreciated venture brands in the market because the parent's quant identity overshadowed the venture franchise. By becoming Deviation Capital, the firm gets to tell its own story to a market that now actively wants quant-native, technically rigorous early-stage capital. The brand reset is also a fundraising tactic: independent GPs raise larger funds at better economics than captive platforms.
The risk is execution. Spinouts often fumble the first vintage post-independence as new infrastructure, ops, and back office build out. Founders' meetings can get scheduled later, comp issues can ripple, and existing LPs can sometimes use the moment to renegotiate. We will be watching for the next named fund vehicle from Deviation, the size of the LP commitments, and whether marquee follow-ons in WHOOP, Kalshi, and Etched land cleanly.
Our bet: Deviation will become one of the most-respected technical early-stage shops in the AI cycle by 2028, and the next branded fund will be raised at a meaningfully larger size than the average TSV vintage. The combination of the existing portfolio, the Two Sigma technical relationship, and Jonathan Golden's product gravitas in San Francisco is hard to argue with.
Frequently Asked Questions
Is Deviation Capital still affiliated with Two Sigma?
Not as a corporate entity. Deviation is independent. However, the firm maintains a formal relationship that gives it ongoing access to Two Sigma's senior technical talent for sourcing, diligence and portfolio support.
What does Deviation invest in?
Early-stage (Seed and Series A) technical founders applying data and compute to industries spanning consumer, enterprise, and life sciences. Notable portfolio names include WHOOP, Remote, Kalshi, Xaira, Gameto and Etched.
How big is the new fund?
Deviation launches with approximately $2 billion in assets under management across the existing TSV vehicles it acquired in the spinout. A new branded fund vehicle has not been disclosed.
Who runs Deviation Capital?
Founding partners include Colin Beirne (the firm's anchor, who built the predecessor TSV platform), Dusan Perovic, Sidney Costabile, and Jonathan Golden, a former NEA general partner who runs the San Francisco office.
Why does this spinout matter for the venture industry?
It is one of the cleaner examples of a corporate-venture-to-independent-GP transition. As AI-native investing matures, expect more captive venture programs inside banks, insurers, and trading firms to spin out into standalone partnerships with their LPs and portfolios intact.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.